MAG
ARCT icon

Millrace Asset Group’s Arcturus Therapeutics ARCT Stock Holding History

Millrace Asset Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18,087
Closed -$776K – 79
2020
Q3 		$776K Buy
+18,087
New +$898K 0.63% 70

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Millrace Asset Group's ARCT Position: Q4 2020 in Review

Millrace Asset Group sold out of Arcturus Therapeutics (ARCT) in Q4 2020, closing a stake of 18,087 shares — an estimated $776K sold.

Millrace Asset Group first reported a position in ARCT in Q3 2020 and held it in 1 quarter. The position peaked at $776K in Q3 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q4 2020.

  • Millrace Asset Group reported no remaining Arcturus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Millrace Asset Group sold 18,087 Arcturus Therapeutics shares in Q4 2020, an estimated $776K.
  • Millrace Asset Group first reported a position in Arcturus Therapeutics in Q3 2020 and held it in 1 quarter.
  • Millrace Asset Group's Arcturus Therapeutics position peaked at $776K in Q3 2020.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2020.

Based on Millrace Asset Group's 13F filing for Q4 2020, filed 11 Feb 2021.